Speech-Language Pathologists in Malba, NY Accepting Medicare
1 Speech-Language Pathologists found. Showing 1 - 1
 Melissa Elizabeth Marelli, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 17 Boulevard, Malba, NY 11357 Phone: 718-746-1610 |
News Archive
Wellderly study finds link between cognitive decline genes and healthy aging
An eight-year-long accrual and analysis of the whole genome sequences of healthy elderly people, or "Wellderly," has revealed a higher-than-normal presence of genetic variants offering protection from cognitive decline, researchers from the Scripps Translational Science Institute (STSI) reported today in the journal Cell.
Novel pipette technique for study of structural properties of tissues
A collaboration of French and Canadian researchers have found that sucking a portion of a spherical globule of cells into a tiny pipette provides information about the adhesion between cells and the elastic properties of the tissue. The method is a novel approach for the study of the structural properties of tissues, and should offer insights into processes such as embryonic development, tissue growth and cancer. A paper describing the research appears online in Physical Review Letters on May 24.
Failure to accurately assess optic nerve drives IIH overdiagnosis
Researchers put overdiagnosis of idiopathic intracranial hypertension (IIH) down to inaccurate ophthalmoscopic examination in headache patients and wrongly suspecting the condition in young obese women with headaches.
Australian scientists discover cells that cause a common type of childhood leukaemia
Scientists at The Royal Melbourne Hospital and the University of Melbourne in Australia have discovered the cells that cause a common type of childhood leukaemia - T cell Acute Lymphoblastic Leukaemia (T-ALL). Targeting of these cells may lead to improved treatments for this disease and help prevent relapse.
Intermediate dosages of otamixaban reduce acute coronary complications
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy.
› Verified 3 days ago